<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Ancrod,Ancrod.png,Serine endopeptidases,Serine endopeptidases,Acrosin,Adenosine diphosphate,Adenosine triphosphate,Adhesion,Aggregation,Amputation,Anatomical Therapeutic Chemical Classification System" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Ancrod - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Ancrod</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <p><b>Ancrod</b> (also known under its former brand name <b>Arwin®</b> and recently <b>Viprinex®</b>) is an <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">anticoagulant</a>.</p>
<table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="../../../u/p/l/Special%7EUpload_3661.html" class="new" title="Image:Ancrod.png">Image:Ancrod.png</a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Ancrod</div>
</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="../../../i/n/t/International_Union_of_Pure_and_Applied_Chemistry_nomenclature_efd4.html" title="International Union of Pure and Applied Chemistry nomenclature">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">Ancrod, Ophidian l-amino-acid oxidase (l-amino-acid oxygen:oxidoreductase, deaminating)</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="../../../c/a/s/CAS_registry_number_4b20.html" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=EC" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=EC" rel="nofollow">3.4.2&amp;rn=1 EC 3.4.2</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../a/n/a/Anatomical_Therapeutic_Chemical_Classification_System_186e.html" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../p/u/b/PubChem_a50b.html" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../c/h/e/Chemical_formula.html" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../m/o/l/Molecular_mass.html" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">100% after i.v. dosing</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/l/a/Plasma_protein_binding.html" title="Plasma protein binding">Protein binding</a></td>
<td bgcolor="#EEEEEE">95% bound to erythrocytes</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../d/r/u/Drug_metabolism.html" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE">mainly renal</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Biological_half-life.html" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">3 to 5 hours</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../e/x/c/Excretion.html" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/r/e/Pregnancy_category.html" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>X (contraindicated)</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p>Rx only, where available</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/o/u/Route_of_administration.html" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">s.c. injection or i.v. infusion</td>
</tr>
</table>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Basic_Chemical.2C_Pharmacological.2C_and_Marketing_Information"><span class="tocnumber">1</span> <span class="toctext">Basic Chemical, Pharmacological, and Marketing Information</span></a></li>
<li class="toclevel-1"><a href="#Current_Indications_for_Viprinex.C2.AE"><span class="tocnumber">2</span> <span class="toctext">Current Indications for Viprinex®</span></a></li>
<li class="toclevel-1"><a href="#Study_Results_in_Patients_with_early_Ischemic_Stroke"><span class="tocnumber">3</span> <span class="toctext">Study Results in Patients with early Ischemic Stroke</span></a></li>
<li class="toclevel-1"><a href="#Contraindications_and_Precautions"><span class="tocnumber">4</span> <span class="toctext">Contraindications and Precautions</span></a></li>
<li class="toclevel-1"><a href="#Pregnancy"><span class="tocnumber">5</span> <span class="toctext">Pregnancy</span></a></li>
<li class="toclevel-1"><a href="#Side-Effects"><span class="tocnumber">6</span> <span class="toctext">Side-Effects</span></a></li>
<li class="toclevel-1"><a href="#Interactions"><span class="tocnumber">7</span> <span class="toctext">Interactions</span></a></li>
<li class="toclevel-1"><a href="#Necessary_Laboratory_Examinations"><span class="tocnumber">8</span> <span class="toctext">Necessary Laboratory Examinations</span></a></li>
<li class="toclevel-1"><a href="#Dosage_Regime"><span class="tocnumber">9</span> <span class="toctext">Dosage Regime</span></a></li>
<li class="toclevel-1"><a href="#Special_Antidotes"><span class="tocnumber">10</span> <span class="toctext">Special Antidotes</span></a></li>
<li class="toclevel-1"><a href="#Drug_Availablility"><span class="tocnumber">11</span> <span class="toctext">Drug Availablility</span></a></li>
<li class="toclevel-1"><a href="#External_References"><span class="tocnumber">12</span> <span class="toctext">External References</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Basic_Chemical.2C_Pharmacological.2C_and_Marketing_Information" id="Basic_Chemical.2C_Pharmacological.2C_and_Marketing_Information"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Basic Chemical, Pharmacological, and Marketing Information">edit</a>]</span> <span class="mw-headline">Basic Chemical, Pharmacological, and Marketing Information</span></h2>
<p>Arwin® was marketed in Germany and Austria, where it was withdrawn in the 1980's after it was used for some decades. Arwin® and Viprinex® are brand names of Knoll Pharma and Nordmark, respectively (both belonging to BASF Group). Currently, Viprinex® is approved in a variety of countries, but not in the USA. However, the <a href="../../../f/d/a/FDA_274c.html" title="FDA">FDA</a> has granted a 'fast-track status' for the indication <a href="../../../i/s/c/Ischemic_stroke.html" title="Ischemic stroke">ischemic stroke</a>, for which phase III studies have been conducted in 2005 and 2006, as stated below.</p>
<p>Ancrod has a triple mode of action. The exact structure and chemical data such as molecular weight are unknown, but it has been elaborated that the glycosylation of the molecule is an important factor. Glycosylation is remarkably homogenous with the major oligosaccharide accounting for approximately 90% of the total sugar content. Some in vitro reactions have been explored in very detail (see ref. #2, www.blckwell-synergy). Experimentally it was found that ancrod's actions are <a href="../../../f/a/d/FAD_233d.html" title="FAD">FAD</a> dependent and that the substance has interesting apoptotic properties (causing programmed cell death), which still remain to be elaborated.</p>
<p>Ancrod must be prepared from the crude <a href="../../../v/e/n/Venom.html" title="Venom">venom</a> of the Malayan pit <a href="../../../v/i/p/Viper.html" title="Viper">viper</a> (Agkistrodon rhodostoma, also termed Calloselasma rhodostoma) and belongs to the group of proteolytic <a href="../../../e/n/z/Enzyme.html" title="Enzyme">enzymes</a>. Ancrod may also be found in the venoms of many poisonous snakes (crotalids, elapids and viperids) in general, but the Malayan pit viper is most suitable due to a high concentration of ancrod in its venom. For its preparation a snake farm, very skilled and well trained staff (for nursing the highly poisonous snakes), and special production facilities are required. This explains the high price of ancrod, because only the ultrapurified enzyme can be used clinically. Therapy with ancrod has to be started in a clinic and, if a response is seen and the drug is well tolerated, it is probably possible to continue drug therapy on an outpatient basis later.</p>
<p>The halflife of ancrod is 3 to 5 hours and the drug is cleared from plasma mainly renal.</p>
<p>Due to its special mode of action (see below) and its price Arwin® has never been used as 'normal' anticoagulant such as <a href="../../../h/e/p/Heparin.html" title="Heparin">heparin</a>, but only for the symptomatic treatment of moderate to severe forms of peripheral arterial circulatory disorders such as those resulting from years of heavy smoking and/or arteriosclerosis. However, Viprinex® has been found to be indicated for the treatment or prophylaxis of a variety of many other <a href="../../../c/o/a/Coagulation.html" title="Coagulation">coagulation</a> related disorders (please refer to section 'current indications of Viprinex®').</p>
<p>The substance is intended for parenteral, namely subcutaneous (s.c.) injection and intravenous (i.v.) infusion, and indirectly inhibits <a href="../../../a/g/g/Aggregation.html" title="Aggregation">aggregation</a>, <a href="../../../a/d/h/Adhesion.html" title="Adhesion">adhesion</a>, and <a href="../../../r/e/l/Release.html" title="Release">release</a> of <a href="../../../t/h/r/Thrombocytes.html" title="Thrombocytes">thrombocytes</a> mediated through the action of a fibrinogen degradation product (FDP). It also cleaves and therefore inactivates a significant part of circulating plasma <a href="../../../f/i/b/Fibrinogen.html" title="Fibrinogen">fibrinogen</a>. Fibrinogen is often found in increased concentrations in arteriae with impaired circulation. This leads to a pathologically increased blood <a href="../../../v/i/s/Viscosity.html" title="Viscosity">viscosity</a> and thereby to a worsening of symptoms of the circulation disorder (more intense pain, decreased mobility of the limb and decreased temperature, need for partial or even total limb <a href="../../../a/m/p/Amputation.html" title="Amputation">amputation</a>). The blood viscosity in patients receiving ancrod is progressively reduced by 30 to 40% of the pretreatment levels. The decreased viscosity is directly attributable to lowered fibrinogen levels and leads to important improvements in blood flow and perfusion of the microcirculation. Erythrocyte flexibility is not affected by normal doses of ancrod. The rheological changes are readily maintained and the viscosity approaches pretreatment values very slowly (within about 10 days) after stopping ancrod. One of the cleavage fibrinogen products, termed 'desAA-Fibrin', acts as cofactor for the <a href="../../../t/p/a/TPA_29c4.html" title="TPA">tPA</a>-induced <a href="../../../p/l/a/Plasminogen.html" title="Plasminogen">plasminogen</a> activation and an increased <a href="../../../f/i/b/Fibrinolysis.html" title="Fibrinolysis">fibrinolysis</a> results in return (profibrinolytic activity of ancrod).</p>
<p>So ancrod decreases as well the blood viscosity in affected arteries, leads to less intense pain, improves physical limb mobility, and faciliates physical and ergo therapy. Finally, ancrod decreases the likelihood of local thrombotic events.</p>
<p>The above mentioned mechanisms also account for the activity of Viprinex® angainst other diseases.</p>
<p>Effects on Other Clotting Factors: Unlike <a href="../../../t/h/r/Thrombin.html" title="Thrombin">thrombin</a>, ancrod does not directly activate <a href="../../../f/a/c/Factor_XIII_d15d.html" title="Factor XIII">Factor XIII</a>, nor does it produce platelet aggregation nor cause the release of <a href="../../../a/d/e/Adenosine_diphosphate.html" title="Adenosine diphosphate">ADP</a>, <a href="../../../a/d/e/Adenosine_triphosphate.html" title="Adenosine triphosphate">ATP</a>, <a href="../../../p/o/t/Potassium.html" title="Potassium">potassium</a>, nor <a href="../../../s/e/r/Serotonin.html" title="Serotonin">serotonin</a> from platelets. Platelet counts and survival time remain normal during ancord therapy.</p>
<p><a name="Current_Indications_for_Viprinex.C2.AE" id="Current_Indications_for_Viprinex.C2.AE"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Current Indications for Viprinex®">edit</a>]</span> <span class="mw-headline">Current Indications for Viprinex®</span></h2>
<p>For the treatment of established <a href="../../../d/e/e/Deep_vein_thrombosis.html" title="Deep vein thrombosis">deep vein thrombosis</a>; central retinal and branch vein thrombosis; <a href="../../../p/r/i/Priapism.html" title="Priapism">priapism</a>; <a href="../../../p/u/l/Pulmonary_hypertension.html" title="Pulmonary hypertension">pulmonary hypertension</a> of embolic origin; <a href="../../../e/m/b/Embolism.html" title="Embolism">embolism</a> after insertion of prosthetic cardiac valves; rethrombosis after thrombolytic therapy and rethrombosis after vascular surgery. It is also indicated for the prevention of deep venous thrombosis after repair of the fractured neck of a femur.</p>
<p>For the treatment of moderate and severe chronic circulatory disorders of peripheral arteries (e.g., <a href="../../../a/r/t/Arteriosclerosis.html" title="Arteriosclerosis">arteriosclerosis</a> obliterans, <a href="../../../t/h/r/Thromboangiitis_obliterans.html" title="Thromboangiitis obliterans">thromboangiitis obliterans</a>, diabetic microangiopathy and <a href="../../../r/a/y/Raynaud%27s_phenomenon.html" title="Raynaud's phenomenon">Raynaud's phenomenon</a>).</p>
<p>Ancrod has been shown to be useful for maintaining anticoagulation in the presence of <a href="../../../h/e/p/Heparin-induced_thrombocytopenia.html" title="Heparin-induced thrombocytopenia">Heparin-induced thrombocytopenia</a> (HIT) and thrombosis.</p>
<p>Physicians should have at any time access to fibrinogen enriched <a href="../../../c/r/y/Cryoprecipitate.html" title="Cryoprecipitate">cryoprecipitate</a>.</p>
<p><a name="Study_Results_in_Patients_with_early_Ischemic_Stroke" id="Study_Results_in_Patients_with_early_Ischemic_Stroke"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Study Results in Patients with early Ischemic Stroke">edit</a>]</span> <span class="mw-headline">Study Results in Patients with early Ischemic Stroke</span></h2>
<p>In a multicenter, parallel, group sequential, randomized, double-blind, placebo-controlled German study of efficacy and safety of i.v. ancrod given within 6 hours after the onset of acute, ischemic stroke and continued for 5 days (called ESTAT study), the early findings for 800 patients were positive, but as the study was expanded to 1,600 patients, placebo was found to be more effective than ancrod and the study was abruptly terminated, mainly because the <a href="../../../m/o/r/Mortality.html" title="Mortality">mortality</a> in the ancrod group was higher. The smaller American study 'Stroke Treatment with Ancrod Trial (STAT)' confirmed the negative outcome for ischemic stroke. However, in the USA ancrod progressed to phase III studies involving approximately 2,000 patients, because some limited beneficial effects may nevertheless be likely.</p>
<p>Neurobiological Technologies, Inc. (NTI) has signed agreements with Nordmark Arzneimittel GmbH &amp; Co KG (Nordmark) and Baxter Pharmaceutical Solutions, LLC (Baxter) to manufacture, fill and package Viprinex® for NTI's Phase III clinical trials in acute ischemic stroke. Nordmark will manufacture the biological active ingredient, ancrod. Date of this agreement was 1st. August 2005.</p>
<p><a name="Contraindications_and_Precautions" id="Contraindications_and_Precautions"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Contraindications and Precautions">edit</a>]</span> <span class="mw-headline">Contraindications and Precautions</span></h2>
<ul>
<li>Known <a href="../../../b/l/e/Bleeding_disorders.html" title="Bleeding disorders">bleeding disorders</a> of any origin or any unexplained excessive bleedings in the past.</li>
<li>Platelet counts of less than 100,000 (even if asymptomatic), exemption&#160;: HIT (Heparin- induced thrombocytopenia).</li>
<li>Planned <a href="../../../s/u/r/Surgery.html" title="Surgery">surgery</a> or short before <a href="../../../d/e/l/Delivery.html" title="Delivery">delivery</a>.</li>
<li>Active <a href="../../../u/l/c/Ulceration.html" title="Ulceration">ulcerations</a> of the GIT.</li>
<li>Any kind of <a href="../../../m/a/l/Malignant.html" title="Malignant">malignant</a> disease.</li>
<li><a href="../../../r/e/n/Renal_stones.html" title="Renal stones">Renal stones</a> (increased likelihood of significant urological bleeding).</li>
<li>Severe and uncontrolled <a href="../../../a/r/t/Arterial_hypertension.html" title="Arterial hypertension">arterial hypertension</a>.</li>
<li>Active <a href="../../../p/u/l/Pulmonary_tuberculosis.html" title="Pulmonary tuberculosis">pulmonary tuberculosis</a>.</li>
<li>Impaired <a href="../../../f/i/b/Fibrinolysis.html" title="Fibrinolysis">fibrinolysis</a>.</li>
<li>Severe <a href="../../../l/i/v/Liver_disease.html" title="Liver disease">liver disease</a>.</li>
<li>Manifest or impending <a href="../../../s/h/o/Shock.html" title="Shock">shock</a>.</li>
<li>I.M.-Injection&#160;: Ancrod should not be injected i.m., because of rapid induction of neutralizing <a href="../../../a/n/t/Antibodies.html" title="Antibodies">antibodies</a> and therefore <a href="../../../d/r/u/Drug_resistance.html" title="Drug resistance">drug resistance</a>.</li>
</ul>
<p><a name="Pregnancy" id="Pregnancy"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Pregnancy">edit</a>]</span> <span class="mw-headline">Pregnancy</span></h2>
<p>Category X&#160;: Ancrod was not found to be <a href="../../../t/e/r/Teratogenic.html" title="Teratogenic">teratogenic</a> in animal studies, but some fetal deaths occurred as a result of placental hemorrhages in animals given high doses; therefore, it should not be used during pregnancy as the defibrinogenation mechanism of ancrod might be expected to interfere with the normal implantation of the fertilized egg.</p>
<p><a name="Side-Effects" id="Side-Effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Side-Effects">edit</a>]</span> <span class="mw-headline">Side-Effects</span></h2>
<ul>
<li>Hypersensitivity reactions&#160;: Local or generalized skin reactions (<a href="../../../r/a/s/Rash.html" title="Rash">rash</a> and <a href="../../../u/r/t/Urticaria.html" title="Urticaria">urticaria</a>); appearance of neutralizing antibodies to ancrod with partial or total loss of ancrod activity (drug resistance).</li>
<li>Sometimes pain at injection site (normally mild). This side-effect may be, if necessary, treated with local or oral antihistaminic drugs (e.g., <a href="../../../c/l/e/Clemastine.html" title="Clemastine">clemastine</a>, or <a href="../../../d/i/p/Diphenhydramine.html" title="Diphenhydramine">diphenhydramine</a>). Bleeding at injection site, <a href="../../../t/h/r/Thrombophlebitis.html" title="Thrombophlebitis">thrombophlebitis</a> at local veins, and (paradoxical) arterial thrombotic events.</li>
<li>Occasionally deposition of cleaved fibrinogen derivates in the splen resulting in <a href="../../../s/p/l/Splenomegaly.html" title="Splenomegaly">splenomegaly</a>; rupture is possible, if the <a href="../../../s/p/l/Spleen.html" title="Spleen">spleen</a> is palpated too strongly (life-threatening bleeding and need of <a href="../../../s/p/l/Splenectomy.html" title="Splenectomy">splenectomy</a> may result).</li>
<li>Specific side-effects are local and systemic bleeding events. Local bleeding events may be treated with local pressure or <a href="../../../s/u/r/Surgical_dressings.html" title="Surgical dressings">surgical dressings</a>, if necessary. Compared with other anticoagulants the risk of systemic bleeding is relatively low. If systemic bleeding is severe enough to warrant fast reversal of ancrod action, fibrinogen should be substituted (please refer to section 'special antidotes').</li>
<li>Occasionally, increased headache has been found in patients with known <a href="../../../m/i/g/Migraine.html" title="Migraine">migraine</a>.</li>
<li>Also, <a href="../../../c/h/i/Chills.html" title="Chills">chills</a> and <a href="../../../f/e/v/Fever.html" title="Fever">fever</a> may occur infrequently.</li>
</ul>
<p>Thrombocytopenia as side-effect has never been noticed with ancrod in contrast to heparin.</p>
<p><a name="Interactions" id="Interactions"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Interactions">edit</a>]</span> <span class="mw-headline">Interactions</span></h2>
<p>The risk of bleeding events is increased, if other anticoagulants (e.g., coumarines such as <a href="../../../w/a/r/Warfarin.html" title="Warfarin">warfarin</a>), inhibitors of thrombocytic aggregation such as <a href="../../../a/s/p/Aspirin.html" title="Aspirin">aspirin</a>, or <a href="../../../f/i/b/Fibrinolytics.html" title="Fibrinolytics">fibrinolytics</a> such as <a href="../../../u/r/o/Urokinase.html" title="Urokinase">urokinase</a> are used concomitantly or within a period of 10 days after discontinuation of ancrod.</p>
<p>Plasma expanders: Artificial plasma expanders (e.g. <a href="../../../d/e/x/Dextran.html" title="Dextran">dextran</a>) may cause severe bleeding in defibrinated patients and should not be administered during or within 10 days of ancrod therapy.</p>
<p>Severe GIT-bleedings may result from the concomitant use of <a href="../../../n/s/a/NSAID_a6d3.html" title="NSAID">NSAIDs</a>, <a href="../../../g/l/u/Glucocorticosteroids.html" title="Glucocorticosteroids">glucocorticosteroids</a>, <a href="../../../n/i/a/Niacin.html" title="Niacin">niacin</a> derivates, or other drugs with ulcerogenic potential.</p>
<p>The danger of <b>thromboembolic events</b> is considerably increased, if ancrod is given <i>immediately</i> after systemic fibrinolytics.</p>
<p><a name="Necessary_Laboratory_Examinations" id="Necessary_Laboratory_Examinations"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Necessary Laboratory Examinations">edit</a>]</span> <span class="mw-headline">Necessary Laboratory Examinations</span></h2>
<p>Pretreatment investigations: A complete blood cell count, including platelet count, and fibrinogen determination should be obtained before treatment.</p>
<p>In case of significant bleeding events&#160;: <a href="../../../h/e/m/Hemoglobin.html" title="Hemoglobin">Hemoglobin</a>, <a href="../../../h/e/m/Hematocrit.html" title="Hematocrit">hematocrit</a>, and a complete red cell status should be obtained. Blood pressure values should be monitored to exclude the development of an impending hemorrhagic shock.</p>
<p>Laboratory Control during Induction Dose Infusion: The fibrinogen concentration should be measured at six hours intervals during, and at the end of the infusion of the induction dose.</p>
<p>Fibrinogen should also be measured at regular intervals, at the same time of the day, during the maintenance dose infusions or injections.</p>
<p><a name="Dosage_Regime" id="Dosage_Regime"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Dosage Regime">edit</a>]</span> <span class="mw-headline">Dosage Regime</span></h2>
<p>Usually, a (high) induction dose is given as i.v. infusion for 12 hours to reach the desired decreased level of fibrinogen quickly, followed by regular lower dose infusions or s.c.-injections. In any case, the exact dosage is determined by an experienced clinician treating the condition for which ancrod is given. He or she will determine also the duration of treatment.</p>
<p><a name="Special_Antidotes" id="Special_Antidotes"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Special Antidotes">edit</a>]</span> <span class="mw-headline">Special Antidotes</span></h2>
<p>In case that quick reversal of Arwin® action was required, a special <a href="../../../a/n/t/Antidote.html" title="Antidote">antidote</a> was available from Knoll at no cost; it was a <a href="../../../b/l/o/Blood_plasma.html" title="Blood plasma">serum</a> from the <a href="../../../g/o/a/Goat.html" title="Goat">goat</a> containing a high concentration of antibodies to ancrod, with which ancrod could be neutralized rapidly. Nonetheless, it was often necessary to restore normal fibrinogen activity with cryoprecipitate after use of the antidot, because the body needs some time to restore fibrinogen levels on its own. The aforementioned antidot is not obtainable any longer. Now, cryoprecipitate should be administered alone to raise the plasma fibrinogen concentrations to safe levels. Whole <a href="../../../b/l/o/Blood_transfusions.html" title="Blood transfusions">blood transfusions</a> are also suitable, particular where cryoprecipitate is not available. Anemia related to severe bleeding events can be corrected with <a href="../../../p/a/c/Packed_red_blood_cells.html" title="Packed red blood cells">packed red blood cells</a> or whole blood.</p>
<p><a name="Drug_Availablility" id="Drug_Availablility"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: Drug Availablility">edit</a>]</span> <span class="mw-headline">Drug Availablility</span></h2>
<p>Viprinex® is delivered in vials containing 70 Biological Units each.</p>
<p><a name="External_References" id="External_References"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/c/Ancrod.html" title="Edit section: External References">edit</a>]</span> <span class="mw-headline">External References</span></h2>
<ul>
<li>H. P. T. Ammon (Editor)&#160;: Arzneimittelneben- und -wechselwirkungen, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart (4th. ed.), 2001, <a href="../../../b/o/o/Special%7EBooksources_ed7b.html" class="internal">ISBN 3-8047-1717-9</a>, in German</li>
<li><a href="http://www.blackwell-synergy.com/servlet/useragent?func=synergy&amp;synergyAction=showAbstract&amp;doi=10.1046/j.1432-1327.2001.02321.x" class="external free" title="http://www.blackwell-synergy.com/servlet/useragent?func=synergy&amp;synergyAction=showAbstract&amp;doi=10.1046/j.1432-1327.2001.02321.x" rel="nofollow">http://www.blackwell-synergy.com/servlet/useragent?func=synergy&amp;synergyAction=showAbstract&amp;doi=10.1046/j.1432-1327.2001.02321.x</a> (chemical details of ancrod)</li>
<li><a href="http://archiv.ub.uni-heidelberg.de/volltextserver/volltexte/2003/3368/pdf/diss03-20.pdf" class="external free" title="http://archiv.ub.uni-heidelberg.de/volltextserver/volltexte/2003/3368/pdf/diss03-20.pdf" rel="nofollow">http://archiv.ub.uni-heidelberg.de/volltextserver/volltexte/2003/3368/pdf/diss03-20.pdf</a> (Some results of clinical research) - in German</li>
<li><a href="http://www.uni-leipzig.de/forsch00/49000/49219.htm" class="external free" title="http://www.uni-leipzig.de/forsch00/49000/49219.htm" rel="nofollow">http://www.uni-leipzig.de/forsch00/49000/49219.htm</a> (negative study results in ischemic strike), in German</li>
<li><a href="http://www.ntii.com/products/viprinex.shtml" class="external free" title="http://www.ntii.com/products/viprinex.shtml" rel="nofollow">http://www.ntii.com/products/viprinex.shtml</a> (phase III studies in the USA regarding ischemic stroke)</li>
<li><a href="http://www.prohostonline.com/ImpactingNews/IN%201%2028%2005.pdf" class="external free" title="http://www.prohostonline.com/ImpactingNews/IN%201%2028%2005.pdf" rel="nofollow">http://www.prohostonline.com/ImpactingNews/IN%201%2028%2005.pdf</a> (FDA grants fast-track status for indication ischemic stroke)</li>
<li><a href="http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20V)/VIPRINEX.html" class="external free" title="http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20V)/VIPRINEX.html" rel="nofollow">http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20V)/VIPRINEX.html</a> (scientific information on Viprinex®)</li>
<li><a href="http://www.findarticles.com/p/articles/mi_m0DHC/is_8_17/ai_n14792504" class="external free" title="http://www.findarticles.com/p/articles/mi_m0DHC/is_8_17/ai_n14792504" rel="nofollow">http://www.findarticles.com/p/articles/mi_m0DHC/is_8_17/ai_n14792504</a> (marketing agreement Neurobiological - Nordmark - Baxter)</li>
</ul>
<div class="NavFrame" style="clear:both;">
<div class="NavHead" style="background:#e7dcc3;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; position:absolute; width:auto; left:0.5em;"><a href="../../../s/e/r/Template%7ESerine_endopeptidases_c70a.html" title="Template:Serine endopeptidases"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../s/e/r/Template%7ESerine_endopeptidases_c70a.html" class="external text" title="http://en.wikipedia.org../../../s/e/r/Template%7ESerine_endopeptidases_c70a.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<b><a href="../../../e/n/d/Endopeptidase.html" title="Endopeptidase">Endopeptidases</a>: <a href="../../../s/e/r/Serine_protease.html" title="Serine protease">serine proteases/serine endopeptidases</a> (<a href="../../../e/c/_/EC_number_9459.html" title="EC number">EC</a> 3.4.21)</b></div>
<div class="NavContent" style="margin:0.5em; font-size:0.9em;">
<p><a href="../../../t/r/y/Trypsin.html" title="Trypsin">Trypsin</a> - <a href="../../../c/h/y/Chymotrypsin.html" title="Chymotrypsin">Chymotrypsin</a> - <a href="../../../e/l/a/Elastase.html" title="Elastase">Elastase</a> (<a href="../../../n/e/u/Neutrophil_elastase.html" title="Neutrophil elastase">Neutrophil</a>, <a href="../../../p/a/n/Pancreatic_elastase.html" title="Pancreatic elastase">Pancreatic</a>) - <a href="../../../e/n/t/Enteropeptidase.html" title="Enteropeptidase">Enteropeptidase</a></p>
<p><a href="../../../a/c/r/Acrosin.html" title="Acrosin">Acrosin</a> - <a href="../../../p/r/o/Pronase.html" title="Pronase">Pronase</a> - <a href="../../../p/r/o/Proprotein_convertases.html" title="Proprotein convertases">Proprotein convertases</a> (<a href="../../../p/r/o/Proprotein_convertase_1.html" title="Proprotein convertase 1">1</a>, <a href="../../../p/r/o/Proprotein_convertase_2.html" title="Proprotein convertase 2">2</a>) - <a href="../../../s/u/b/Subtilisin.html" title="Subtilisin">Subtilisin</a>/<a href="../../../f/u/r/Furin.html" title="Furin">Furin</a></p>
<p><i>Immune</i> (<a href="../../../c/h/y/Chymase.html" title="Chymase">Chymase</a>, <a href="../../../g/r/a/Granzyme.html" title="Granzyme">Granzyme</a>, <a href="../../../t/r/y/Tryptase.html" title="Tryptase">Tryptase</a>, <a href="../../../p/r/o/Proteinase_3.html" title="Proteinase 3">Proteinase 3/Myeloblastin</a>) - <i>Venombin</i> (<strong class="selflink">Ancrod</strong>, <a href="../../../b/a/t/Batroxobin.html" title="Batroxobin">Batroxobin</a>)</p>
<p><i>Complement system:</i> <a href="../../../b/f/_/BF_%28protein%29_6b63.html" title="BF (protein)">Factor B</a> - <a href="../../../d/f/_/DF_%28protein%29_2db2.html" title="DF (protein)">Factor D</a> - <a href="../../../c/o/m/Complement_factor_I_5d1d.html" title="Complement factor I">Factor I</a> - <a href="../../../m/a/n/Mannose-binding_protein-associated_serine_protease.html" title="Mannose-binding protein-associated serine protease">MASP</a> (<a href="../../../m/a/s/MASP1_%28protein%29_7400.html" title="MASP1 (protein)">MASP1</a>, <a href="../../../m/a/s/MASP2_%28protein%29_ebf6.html" title="MASP2 (protein)">MASP2</a>)</p>
<p><i>Coagulation factors:</i> <a href="../../../t/h/r/Thrombin.html" title="Thrombin">Thrombin</a> - <a href="../../../f/a/c/Factor_VII_b679.html" title="Factor VII">Factor VIIa</a> - <a href="../../../f/a/c/Factor_IX_28e3.html" title="Factor IX">Factor IXa</a> - <a href="../../../f/a/c/Factor_X_3cdb.html" title="Factor X">Factor Xa</a> - <a href="../../../f/a/c/Factor_XI_8f32.html" title="Factor XI">Factor XIa</a> - <a href="../../../f/a/c/Factor_XII_5139.html" title="Factor XII">Factor XIIa</a> - <a href="../../../k/a/l/Kallikrein.html" title="Kallikrein">Kallikrein</a> (<a href="../../../p/r/o/Prostate_specific_antigen.html" title="Prostate specific antigen">PSA</a>) - <i>Fibrinolysis:</i> <a href="../../../p/l/a/Plasmin.html" title="Plasmin">Plasmin</a> - <a href="../../../t/i/s/Tissue_plasminogen_activator.html" title="Tissue plasminogen activator">Tissue plasminogen activator</a> - <a href="../../../u/r/o/Urokinase.html" title="Urokinase">Urinary plasminogen activator</a></p>
</div>
</div>

<!-- 
Pre-expand include size: 27825 bytes
Post-expand include size: 9639 bytes
Template argument size: 2691 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/n/c/Ancrod.html">http://en.wikipedia.org../../../a/n/c/Ancrod.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Category</a>: <span dir='ltr'><a href="../../../a/n/t/Category%7EAnticoagulants_e341.html" title="Category:Anticoagulants">Anticoagulants</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/n/c/Ancrod.html">Article</a></li><li id="ca-talk"
	       class="new"	       ><a href="../../../a/n/c/Talk%7EAncrod_eab3.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Ancrod">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 01:09, 8 April 2007 by Wikipedia user ThinkerThoughts. Based on work by Wikipedia user(s) <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../u/t/h/User%7EUthbrian_6843.html" title="User:Uthbrian">Uthbrian</a>, <a href="../../../s/a/g/User%7ESagabot_42ff.html" title="User:Sagabot">Sagabot</a>, <a href="../../../k/e/t/User%7EKetiltrout_7f16.html" title="User:Ketiltrout">Ketiltrout</a>, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, <a href="../../../u/r/o/User%7EUrod_afcd.html" title="User:Urod">Urod</a>, <a href="../../../s/m/a/User%7ESmackBot_cc7a.html" title="User:SmackBot">SmackBot</a>, <a href="../../../d/r/e/User%7EDreadlocke_8280.html" title="User:Dreadlocke">Dreadlocke</a>, <a href="../../../s/k/a/User%7ESkapur_f77a.html" title="User:Skapur">Skapur</a> and KlausFr and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
